← Back to screener

CATALYST PHARMACEUTICALS, INC. CPRX

Rank #1192 · Nasdaq · $3.9B market cap
Audited by GRANT THORNTON LLP, no going-concern flag in the latest filing.
Score
52.3
P/E
53.9
P/B
12.82
ROE
23.8%
Op. Margin
21.8%
Debt Ratio
41%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E 53.9x, P/B 12.82x. Ranks in the top 68% of the universe.

Profitability ★★★★☆
Excellent

ROE 23.8%. Ranks in the top 18% of the universe.

Safety ★★★★☆
Good

Debt ratio 41%. Ranks in the top 21% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 85.9% year over year. Ranks in the top 4% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.0B–314
2012–$-0.0B$-0.0B$0.0B–2489
2013–$-0.0B$-0.0B$0.0B–2167
2014$0.0B$-0.0B$-0.0B$0.0B–106
2015$0.0B$-0.0B$-0.0B$0.0B–59
2016$0.0B$-0.0B$-0.0B$0.0B–22
2017$0.0B$-0.0B$-0.0B$0.0B–7
2018$0.0B$-0.0B$-0.0B$0.0B–11
2019$0.0B$-0.0B$-0.0B$0.1B-7059.012
2020$0.0B$-0.0B$-0.0B$0.1B-7059.031
2021$0.1B$0.0B$0.0B$0.1B31.145
2022$0.1B$0.0B$0.1B$0.1B34.735
2023$0.1B$0.1B$0.0B$0.2B37.244
2024$0.2B$0.1B$0.1B$0.2B47.540
2025$0.4B$0.1B$0.1B$0.3B21.841

← See the full screener